Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.23.1
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2020 $ 765 $ 14,471 $ 39,050,260 $ (23,648,898) $ (1,893,897) $ 13,522,701
Balance, shares at Dec. 31, 2020 764,618 14,471,403        
Sale of common stock – investors $ 2,507 6,052,493 6,055,000
Sale of common stock - investors, shares   2,507,194        
Issuance of common stock - noteholders $ 304 422,368 422,672
Issuance of common stock - note holders, shares   303,483        
Issuance of common stock - consultants $ 1,819 3,198,375 3,200,194
Issuance of common stock - consultants, shares   1,819,272        
Issuance of common stock - employees $ 2,891 3,289,299 3,292,190
Issuance of common stock - employees, shares   2,891,227        
Issuance of common stock upon exercise of warrants $ 69,213 180,272,201 180,341,414
Issuane of common stock upon exercise of warrants, shares   69,212,800        
Offering costs -exercise of warrants (12,380,315) (12,380,315)
Issuance of common stock for acquisition $ 3,500 10,131,500 10,135,000
Issuance of common stock for acquisition, shares   3,500,000        
Share-based compensation 10,077,275 479,161 10,556,436
Conversion under notes payable $ 11,551 32,418,206 32,429,757
Conversion under notes payable, shares   11,551,384        
Exercise of warrant liabilities 338,020,680 338,020,680
Shares reserved for future issuance of common stock as consideration for the Emmersive asset acquisition 7,400,000 7,400,000
Conversion of preferred stock to common $ (765) $ 765
Conversion of preferred stock to common, shares (764,618) 764,618        
Noncontrolling interest 27,441,251 27,441,251
Net income (loss) (788,601,430) (3,834,756) (792,436,186)
Balance at Sep. 30, 2021 $ 107,021 617,952,342 (812,250,328) 22,191,759 (171,999,206)
Balance, shares at Sep. 30, 2021 107,021,381        
Balance at Jun. 30, 2021 $ 59,927 244,026,879 (269,787,198) (1,843,320) (27,543,712)
Balance, shares at Jun. 30, 2021 59,927,241        
Sale of common stock – investors $ 1,007 2,798,993 2,800,000
Sale of common stock - investors, shares   1,007,194        
Issuance of common stock - noteholders
Issuance of common stock - note holders, shares          
Issuance of common stock - consultants $ 425 1,163,434 1,163,859
Issuance of common stock - consultants, shares   425,000        
Issuance of common stock - employees $ 30 (30)
Issuance of common stock - employees, shares   30,000        
Issuance of common stock upon exercise of warrants $ 37,470 92,518,525 92,555,995
Issuane of common stock upon exercise of warrants, shares   37,469,814        
Offering costs -exercise of warrants (5,001,251) (5,001,251)
Issuance of common stock for acquisition $ 2,750 8,879,750 8,882,500
Issuance of common stock for acquisition, shares   2,750,000        
Share-based compensation 5,023,571 479,161 5,502,732
Conversion under notes payable $ 5,412 20,175,838 20,181,250
Conversion under notes payable, shares   5,412,132        
Exercise of warrant liabilities 248,366,633 248,366,633
Noncontrolling interest 27,441,251 27,441,251
Net income (loss) (542,463,130) (3,885,333) (546,348,463)
Balance at Sep. 30, 2021 $ 107,021 617,952,342 (812,250,328) 22,191,759 (171,999,206)
Balance, shares at Sep. 30, 2021 107,021,381        
Balance at Dec. 31, 2021 $ 150,118 850,096,635 (736,821,840) 20,262,129 133,687,042
Balance, shares at Dec. 31, 2021 150,118,024        
Issuance of common stock - consultants $ 40 102,523 102,563
Issuance of common stock - consultants, shares   40,000        
Share-based compensation 3,122,647 3,122,647
Exercise of warrant liabilities 227,949,858 227,949,858
Net income (loss) (326,001,907) (87,446,819) (413,448,726)
Issuance of common stock – noteholders, net of offering costs $ 6,047 6,780,620 6,786,667
Issuance of common stock- noteholders, net of offering costs, shares   6,046,667        
Warrants exercised, net of offering costs $ 81,983 100,954,855 101,036,839
Warrants exercised, net of offering costs, shares   81,982,969        
Write off of investments 927,875 927,875
Investment in Magnifi U (1,045,756) (1,045,756)
Common stock issued by Cryptyde, Inc. 12,001,000 12,001,000
Spin-off of Cryptyde, Inc. (11,936,218) 299,608 (11,636,610)
Balance at Sep. 30, 2022 $ 238,188 1,185,884,492 (1,062,758,966) (63,880,316) 59,483,398
Balance, shares at Sep. 30, 2022 238,187,660        
Balance at Jun. 30, 2022 $ 233,141 1,181,292,871 (963,776,852) 4,580,064 222,329,225
Balance, shares at Jun. 30, 2022 233,140,993        
Share-based compensation 1,040,883 1,040,883
Net income (loss) (98,982,114) (68,756,763) (167,738,877)
Issuance of common stock – noteholders, net of offering costs $ 5,047 4,591,620 4,596,667
Issuance of common stock- noteholders, net of offering costs, shares   5,046,667        
Investment in Magnifi U (744,500) (744,500)
Balance at Sep. 30, 2022 $ 238,188 $ 1,185,884,492 $ (1,062,758,966) $ (63,880,316) $ 59,483,398
Balance, shares at Sep. 30, 2022 238,187,660